SRTS President & General Counsel reports new insider share purchases
Rhea-AI Filing Summary
Sensus Healthcare, Inc. insider Michael Sardano, who serves as President, General Counsel, and a director of the company, reported open-market purchases of SRTS common stock. On 11/11/2025, he bought 1,000 shares of common stock at a price of $4.26 per share, bringing his directly owned holdings to 117,839 shares.
On the same date, his spouse purchased 766 shares at $4.27 per share and 234 shares at $4.34 per share, for a total of 1,000 shares held in the spouse’s name. The filing notes that Sardano disclaims beneficial ownership of the shares held by his spouse.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 1,000 | $4.26 | $4K |
| Purchase | Common Stock | 766 | $4.27 | $3K |
| Purchase | Common Stock | 234 | $4.34 | $1K |
Footnotes (1)
- F1. Shares held by Mr. Sardano's spouse, as to which he disclaims beneficial ownership.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Sensus Healthcare (SRTS) report for Michael Sardano?
The filing reports that Michael Sardano, President, General Counsel, and director of Sensus Healthcare, Inc. (SRTS), purchased SRTS common stock in open-market transactions on 11/11/2025, and also reported purchases made by his spouse.
What is Michael Sardano’s total direct ownership in Sensus Healthcare after the reported trades?
Following the reported transaction on 11/11/2025, Michael Sardano beneficially owns 117,839 shares of Sensus Healthcare common stock in direct ownership.
What roles does Michael Sardano hold at Sensus Healthcare (SRTS)?
Michael Sardano is reported as both a director and an officer of Sensus Healthcare, serving as President and General Counsel.